Table 1.
Clinical characteristics of ARF cohort with ES.
| Characteristic | Survivors (n = 24) | Non-survivors (n = 6) | Entire cohort (n = 30) | P-value |
|---|---|---|---|---|
| GENDER | 1.000 | |||
| Male | 12 (50%) | 3 (50%) | 15 (50%) | |
| Female | 12 (50%) | 3 (50%) | 15 (50%) | |
| RACE | 0.713 | |||
| Caucasian | 18 (75%) | 6 (100%) | 24 (80%) | |
| African-American | 4 (17%) | 4 (13%) | ||
| Other | 2 (8%) | 2 (7%) | ||
| PRIMARY DIAGNOSIS | 0.831 | |||
| Hematologic malignancy | 11 (46%) | 4 (67%) | 14 (50%) | |
| Solid tumor | 9 (38%) | 2 (33%) | 11 (37%) | |
| Other | 4 (17%) | 4 (13%) | ||
| BMT TYPE | 1.000 | |||
| Allogeneic | 16 (67%) | 4 (67%) | 20 (67%) | |
| Auto | 8 (33%) | 2 (33%) | 10 (33%) | |
| G-CSF/GM-CSF | 17 (71%) | 2 (33%) | 19 (63%) | 0.156 |
| CONDITIONING REGIMEN | 1.000 | |||
| Myeloablative | 16 (67%) | 5 (83%) | 21 (70%) | |
| Reduced Intensity | 6 (25%) | 1 (17%) | 7 (23%) | |
| Non-Myeloablative | 2 (8%) | 2 (7%) | ||
| TBI | 5 (21%) | 1 (17%) | 6 (20%) | 1.000 |
| TNC × 108/kga | 2.97 (0.01–79.6) | 4.94 (1.5–81) | 3.2 (0–81) | 0.321 |
| CD34 × 106/kga | 7.48 (1.28–103.8) | 9.21 (3.18–57.5) | 8.4 (1.3–103.8) | 0.860 |
| VOD | 5 (21%) | 3 (50%) | 8 (27%) | 0.300 |
| Antifungals | 22 (92%) | 5 (83%) | 27 (90%) | 0.501 |
| Antibiotics | 24 (100%) | 6 (100%) | 30 (100%) | 0.120 |
| Corticosteroids | 20 (83%) | 6 (100%) | 26 (87%) | 0.557 |
a
Values are expressed as median with interquartile range.
ARF, acute respiratory failure; ES, Engraftment syndrome; BMT, bone marrow transplant; TBI, total body irradiation; TNC, total nucleated cell; VOD, veno-occlusive disease; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte-macrophage colony stimulating factor.